6.220
6.22 (0.22%)
As of Aug 19, 2022
La Jolla Pharmaceutical Co [LJPC]
Source:
Company Overview
We are dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA(angiotensin II) injection is approved by theU.S. Food and Drug Administration (FDA)as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA(eravacycline) for injection is approved by the FDA as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older.
Country | United States |
Headquarters | waltham, massachusetts |
Phone Number | 617-715-3600 |
Industry | manufacturing |
CEO | Larry Edwards |
Website | ljpc.com |